Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Avenue Therapeutics Inc

Healthcare US ATXI

0.32USD
0.00(0%)

Last update at 2026-06-24T15:32:00Z

Day Range

0.320.35
LowHigh

52 Week Range

0.150.97
LowHigh

Fundamentals

  • Previous Close 0.32
  • Market Cap2.11M
  • Volume3008
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM1.40M
  • Revenue Per Share TTM0.45
  • Gross Profit TTM 1.40M
  • Diluted EPS TTM-0.93

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -2.94700M -11.69600M -10.48800M -3.60300M -3.73100M
Minority interest 0.04M 0.04M 0.11M 0.05M -
Net income -2.90900M -11.65200M -10.37700M 2.05M -3.72400M
Selling general administrative 3.65M 4.64M 4.18M 5.34M 2.48M
Selling and marketing expenses - - 4.17M - -
Gross profit 1.40M - - - -
Reconciled depreciation - - - - -
Ebit - - -10.48800M -8.04300M -3.73800M
Ebitda -3.28600M -11.69600M 4.05M -8.02300M -3.73800M
Depreciation and amortization - - 14.54M 0.02M 0.00700M
Non operating income net other - - - - -
Operating income -3.28600M -11.28300M -14.54000M -8.04300M -3.73800M
Other operating expenses 4.69M 11.28M 14.54M 8.04M 3.74M
Interest expense - 0.00000M 0.33M 1.16M 0.00700M
Tax provision - - - - -
Interest income 0.12M 0.18M 0.13M 0.02M 0.00700M
Net interest income 0.12M 0.18M -0.20600M -1.14000M 0.00700M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.11100M -5.65100M -0.00700M
Total revenue 1.40M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 4.69M 11.28M 14.54M 8.04M 3.74M
Cost of revenue - - - - -
Total other income expense net 0.34M -0.41300M 4.05M 4.44M 0.00700M
Discontinued operations - - - - -
Net income from continuing ops -2.94700M -11.69600M -10.48800M -3.60300M -3.73100M
Net income applicable to common shares - - - - -3.73100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2.93M 2.67M 1.85M 6.84M 3.96M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.08M 0.08M 0.07M 0.14M 0.11M
Total liab 1.10M 0.82M 1.20M 3.58M 0.51M
Total stockholder equity 1.83M 2.80M 1.58M 3.90M 3.45M
Deferred long term liab - - - - -
Other current liab 1.10M 0.66M 0.80M 2.61M 0.15M
Common stock - - 0.00300M - 0.00200M
Capital stock 0.00000M 0.00000M 0.00300M 0.00000M 0.00200M
Retained earnings -105.48900M -102.58000M -90.92800M -80.55100M -76.99900M
Other liab - - - - -
Good will - - - - -
Other assets 0.08M 0.08M 0.07M 0.00014M -
Cash 2.85M 2.59M 1.78M 6.71M 3.76M
Cash and equivalents - - - - -
Total current liabilities 1.10M 0.82M 1.20M 3.58M 0.51M
Current deferred revenue - - - - -
Net debt -2.85500M -2.59400M -1.78300M -6.70800M -3.76300M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 107.32M 105.38M 92.51M 84.46M 80.45M
Property plant equipment - - - - -
Total current assets 2.85M 2.67M 1.85M 6.84M 3.96M
Long term investments - - - - -
Net tangible assets - - - - 3.45M
Short term investments - - - - -
Net receivables - - - - 0.09M
Long term debt - - - - -
Inventory - - - - 0.11M
Accounts payable 0.09M 0.15M 0.40M 0.97M 0.36M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 0.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00000M -3.00000M - 0.00000M
Change to liabilities - - - 0.35M -0.37700M
Total cashflows from investing activities - - -3.00000M - -
Net borrowings - - - - -
Total cash from financing activities 2.09M 9.84M 7.53M 10.54M 4.38M
Change to operating activities - - - -0.03000M -0.08400M
Net income -2.90900M -11.69600M -10.37700M -3.60300M -3.73100M
Change in cash 0.26M 0.81M -4.92500M 2.94M 0.63M
Begin period cash flow 2.59M 1.78M 6.71M 3.76M 3.13M
End period cash flow 2.85M 2.59M 1.78M 6.71M 3.76M
Total cash from operating activities -1.83300M -9.02600M -9.45100M -7.59600M -3.75000M
Issuance of capital stock 2.09M 1.62M 7.53M 12.01M 5.04M
Depreciation - - - - -
Other cashflows from investing activities - - -3.00000M - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - 0.09M -0.09000M
Sale purchase of stock -0.00400M - 1.23M -1.10400M -
Other cashflows from financing activities 2.09M 8.21M 0.00100M -0.36000M -0.66300M
Change to netincome - - - -4.45200M 0.44M
Capital expenditures 0.00000M 0.00000M 3.00M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.30M 0.18M -0.29000M 0.41M -0.46100M
Stock based compensation 0.67M 1.24M 0.91M 0.65M 0.44M
Other non cash items 0.11M 1.25M 0.31M -5.05000M 4.19M
Free cash flow -1.83300M -9.02600M -12.45100M -7.59600M -3.75000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ATXI
Avenue Therapeutics Inc		 - -% 0.32 - 17.99 1.50 1.03 -0.4154
NVO
Novo Nordisk A/S		 0.03 0.05% 47.45 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.16 2.48% 48.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 8.43 1.80% 476.85 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 7.92 1.28% 625.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Avenue Therapeutics Inc

1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154

Key Executives

Name Title Year Born
Dr. Lindsay Allan Rosenwald Exec. Chairman 1955
Dr. Xiaoqin Lu M.D. Consultant 1975
Dr. Alexandra MacLean M.D. Chief Exec. Officer 1967
Mr. David Jin Interim CFO, COO & Corp. Sec. 1990
Dr. Scott A. Reines M.D., Ph.D. Interim Chief Medical Officer 1947
Srinivas Subramanian Exec. VP NA
Dr. Alexandra MacLean M.D. CEO & Director 1968
Mr. David Jin Interim CFO, COO & Corporate Secretary 1991
Dr. Lindsay Allan Rosenwald Executive Director 1955
Mr. Srinivas Subramanian Executive Vice President 1971

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions